id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2008-E-0315-0007,FDA,FDA-2008-E-0315,Determination of Regulatory Review Period for Purposes of Patent Extension: Fusilev (Levoleucovorin),Notice,General Notice,2011-06-23T04:00:00Z,2011,6,2011-06-23T04:00:00Z,2011-08-23T03:59:59Z,2011-06-23T13:49:49Z,2011-15689,0,0,0900006480e9c061
FDA-2008-E-0315-0006,FDA,FDA-2008-E-0315,FDA\CDER to United States Patent and Trademark Office - Letter,Other,LET-Letter,2011-06-03T04:00:00Z,2011,6,2011-06-03T04:00:00Z,,2011-06-03T14:23:01Z,,0,0,0900006480e3a8a9
FDA-2008-E-0315-0005,FDA,FDA-2008-E-0315,FDA\CDER to United States Patent and Trademark Office - Letter,Other,,2011-06-03T00:00:00Z,2011,6,,,2011-06-03T14:16:04Z,,0,1,0900006480e3611d